Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from Romania
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from Romania ; volume:13 ; number:1 ; day:16 ; month:12 ; year:2013 ; pages:1-2 ; date:12.2013
BMC infectious diseases ; 13, Heft 1 (16.12.2013), 1-2, 12.2013
- Creator
-
Streinu-Cercel, Adrian
- Contributor
-
Trifan, Anca Victorița
Caruntu, Florin Alexandru
Sporea, Ioan
Gheorghe, Liliana Simona
Curescu, Manuela
Diculescu, Mihai Mircea
Voiculescu, Mihai
Pascu, Oliviu
Lonjon-Domanec, Isabelle
Hill, Andrew Martin
Rugină, Sorin
SpringerLink (Online service)
- DOI
-
10.1186/1471-2334-13-S1-P58
- URN
-
urn:nbn:de:1111-2016030311980
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Streinu-Cercel, Adrian
- Trifan, Anca Victorița
- Caruntu, Florin Alexandru
- Sporea, Ioan
- Gheorghe, Liliana Simona
- Curescu, Manuela
- Diculescu, Mihai Mircea
- Voiculescu, Mihai
- Pascu, Oliviu
- Lonjon-Domanec, Isabelle
- Hill, Andrew Martin
- Rugină, Sorin
- SpringerLink (Online service)
Other Objects (12)
Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
Bariatric Nutritional Intervention in Obese Patients with Compensated Liver Cirrhosis: A Four-Year Prospective Study
Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray
Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype
Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
Bariatric Nutritional Intervention in Obese Patients with Compensated Liver Cirrhosis: A Four-Year Prospective Study
Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray
Effect of laparoscopic splenectomy in patients with Hepatitis C and cirrhosis carrying IL28B minor genotype
Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure
Tenofovir disoproxil fumarate reduce incidence of HCC development in CHB-patients with compensated cirrhosis
Bariatric Nutritional Intervention in Obese Patients with Compensated Liver Cirrhosis: A Four-Year Prospective Study
Progression of liver stiffness predicts clinical events in HIV/HCV-coinfected patients with compensated cirrhosis
Lusutrombopag increases hematocytes in a compensated liver cirrhosis patient
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Serum liver fibrosis markers predict hepatic decompensation in compensated cirrhosis
The changes in renal function after a single dose of intravenous furosemide in patients with compensated liver cirrhosis
IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis
Gene expression profiling of HCV genotype 3a initial liver fibrosis and cirrhosis patients using microarray